In an effort to improve targeted gene therapy for head and neck cancer, utilising a similar strategy to the 2009 Kim et al. study, Cho et al. developed a PLR and dextran sulfate (DEX)-based nanocomplex for the delivery of epidermal growth factor receptor (EGFR) siRNA [96]. This evidence concerns the gene EGFR and head and neck cancer.